Business
Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Second Quarter
NEW PRAGUE, Minn., February 10, 2026--Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Second Quarter
About this update from Electromed, Inc.
Strong operational execution results in thirteenth consecutive quarter of year-over-year revenue and net income growth NEW PRAGUE, Minn., February 10, 2026--(BUSINESS WIRE)--Electromed, Inc. ("Electromed") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and six months ended December 31, 2025 ("Q2 FY 2026"). Q2 FY 2026 Company Highlights "I'm thrilled to share our record results for the second quarter of fiscal 2026, which represented our 13th consecutive quarter of year-over-year revenue and net income growth. The Electromed team is executing our strategic growth plan at a high level, delivering over 16% revenue growth accompanied by strong operating leverage and net income of $0.32 per diluted share, a record for Electromed," said Jim Cunniff, Electromed’s President and Chief Executive Officer. "Our Triple Down on Bronchiectasis marketing campaign is generating tremendous physician and patient awareness as we work to serve the nearly 800,000 diagnosed bronchiectasis patients who could benefit from our SmartVest® system. Our strong operational execution, investments in profitable growth, judicious stock buybacks, and maintenance of a strong balance sheet reflect our commitment to driving superior value to our shareholders. Most importantly, we remain dedicated to our mission of helping patients with compromised pulmonary function breathe easier and enjoy an improved quality of life." Q2 FY 2026 Results All amounts below are for the three months ended December 31, 2025, and compare to the three months ended December 31, 2024 ("Q2 FY 2025"). Net revenues grew 16.3% to $18.9 million, from $16.3 million. Revenue in our direct homecare business increased by 18.4% to $17.3 million, from $14.6 million. The increase in revenue was primarily due to an increase in direct sales representatives and higher net revenues per sales representative. Throughout Q2 FY 2026, we averaged 58 homecare direct field sales representatives. The annualized homecare revenue per weighted average direct sales representative in Q2 FY 2026 was $1,200,000, exceeding Electromed’s target range of $1,000,000 to $1,100,000. Non-homecare revenue was $1.6 million. Homecare distributor revenue grew 12.1%, totaling $0.9 million for the three months ended December 31, 2...